$50MSeries C, 18 May 2026
Series C funds a Phase IIb trial of RIPK2 inhibitor AC-101 in ulcerative colitis and other I&I programs.
- Amount
- $50M
- Stage
- Series C
- Announced
- 18 May 2026
- Lead
- OrbiMed
- Other investors
- TCGX, LAV, Cenova Capital, Shenzhen Capital Group, Oriza
- Use of funds
- Series C funds a Phase IIb trial of RIPK2 inhibitor AC-101 in ulcerative colitis and other I&I programs.
- Checked
- Announced by the company
- Sources
- Accro Bioscience raises $50M Series C led by OrbiMed biospace.com
Accro Bioscience raises $50M Series C led by OrbiMed pulse2.com